Company,
About Biomunex
BRINGING FORTH THE NEXT STAGE OF ANTIBODY THERAPIES
Who we are
BIOMUNEX is a biopharmaceutical company based in Paris (France), with an office in Cambridge (Massachusetts, USA).
BIOMUNEX focuses on inventing disruptive biological approaches and bringing breakthrough therapies to patients based on the discovery and development of its next generation bi- and multispecific antibodies, using its proprietary BiXAb® platform.
WHERE DO BIOMUNEX COMES FROM
Founded in 2014 by Dr. Pierre-Emmanuel Gerard and located in the Cochin Hospital bioincubator in Paris, where it has its own laboratories and a team of expert scientists renowned in their respective fields, Biomunex is a clinical stage biotech company which leverages its unique and major technological innovation, the BiXAb® platform to develop innovative drugs in immune-oncology.
Inspired by the initial work of Professor Jean-Pierre Mach and his team, at the UNIL (University of Lausanne, Switzerland), a pioneer in multi-specific antibodies for the treatment of cancer, and by the work of teams from the CNRS (French National Center for Scientific Research), the BiXAb® platform is now fully developed by Biomunex’ teams and protected by a vast intellectual property portfolio.
BiXAb® Technology
The bixab innovation
Our game changing proprietary BiXAb® technology enables BIOMUNEX to discover and develop immunotherapies for multiple cancer types.
Considered to date as a best-in-class, the BiXAb® platform allows the development of bispecific antibodies with excellent drug properties and high industrial production, through a simple, rapid and easy to implement process.
The antibodies resulting from this process have already been demonstrated to target many different types of cancers, both solid and liquid. The BiXAb® technology could also be applied to other therapeutic areas in the future.
Similar to LEGO™, the BiXAb® technology platform format allows the generation of a bispecific antibody from any pair of monospecific monoclonal antibodies in a “Plug & Play” fashion. This process requires no extensive engineering and considerably reduces the development time for BiXAb® antibody production which now requires less than 5 to 6 weeks to generate, produce, purify, and characterize a bispecific antibody.
This timing is considerably lower than most other bispecific platforms in the industry, with an industrial production yield much superior to most of the technologies available on the market.
